Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-06-20
2006-06-20
Wilson, James O. (Department: 1623)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C548S126000
Reexamination Certificate
active
07064215
ABSTRACT:
Organic compounds having the structure I are provided where the variables have the values described herein.Pharmaceutical formulations and medicaments include the organic compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier and may be prepared by mixing the organic compound or a pharmaceutically acceptable salt of the organic compound with a carrier and water. A method of treating a patient includes administering a pharmaceutical formulation or medicament according to the invention to a patient in need thereof.
REFERENCES:
patent: 2002/0103230 (2002-08-01), Renhowe et al.
patent: 2003/0028018 (2003-02-01), Renhowe et al.
patent: 19752990 (1997-11-01), None
patent: WO 97/49699 (1997-06-01), None
patent: WO 00/68206 (2000-11-01), None
patent: WO 01/02369 (2001-01-01), None
patent: WO 01/02369 (2001-01-01), None
patent: WO 01/53268 (2001-07-01), None
Soos et al., “Novel Thermal Rearrangement of Fused Diaryl-v-Triazolium Salts to Neutral Indazole Derivatives.” Journal of Organic Chemistry (1997), 62(4), 1136-1138.
Buchi, G. et al., “Direct Acting, Highly Mutagenic, α-HydroxyN-Nitrosamines from 4-Chloroindoles,”J. Am. Chem. Soc., vol. 108, 1986, pp. 4115-4119; published by American Chemical Society (Washington, D.C.).
Soos, T. et al., “Novel Thermal Rearrangement of Fused Diaryl-v-Triazolium Salts to Neutral Indazole Derivatives. Fused Azolium Salts. 16,”J. Org. Chemistry, vol. 62, No. 4, 1997, pp. 1136-1138; published by American Chemical Society (Washington, D.C.).
Carmeliet, P. et al. “Angiogenesis in Cancer and Other Diseases,” Nature, 407, pp. 249-257 (2000).
Salmon, S. E. et al.,Basic&Clinical Pharmacology, Seventh Edition, edited by B. Katzung, Appleton & Lange, pp. 29, 881-884 (1998).
Milauer, B. et al., “Glioblastoma Growth Inhibited In Vivo by a Dominant-Negative Flk-1 Mutant,”Nature, vol. 367, pp. 576-579 (1994); published by Nature Publishing Group.
Pinedo, H. M. et al., “Translational Research: The Role of VEGF in Tumor Angiogenesis,”The Oncologist 2000, vol. 5 (suppl. 1), pp. 1-2 (2000).
McMahon, G., “VEGF Receptor Signaling in Tumor Angiogenesis,”The Oncologist 2000, vol. 5 (suppl. 1), pp. 3-10 (2000).
Zetter, B. R., “Angiogenesis and Tumor Metastasis,” Annu. Rev. Med., 1998, vol. 49, pp. 407-424; published by Annual Review Inc.
MSNBC News Services, “Mixed results on new cancer drug,” Nov. 9, 2000.
Gura, T., “Systems for Identifying New Drugs Are Often Faulty,”Science, 1997, vol. 278, pp. 1041-1042.
Dermer, G. B., “Another Anniversary for the War on Cancer,”Biotechnology, 1994, vol. 12, p. 320.
Freshney, R. I.,Culture of Animal Cells—A Manual of Basic Technique, 1983, pp. 1-4; published by Alan R. Liss, Inc.
Angiogenesis Foundation, “New Study Shows That Acute Myeloid Leukemia is Angiogenesis-Dependent,” Jan. 4, 2000; www.angio.org
ewsandviews/ archive2000/jan—4—2000.html.
Hussong, J. W. et al., “Evidence of Increased angiogenesis in acute myeloid leukemia,”Blood, 2000, vol. 95(1), pp. 309-313; The American Society of Hematology.
Kerbel, R. S., “Tumor Angiogenesis: Past, Present and Near Future,”Carcinogenesis, 2000, vol. 21(3), pp. 505-515; Oxford University Press.
Lundberg, L. G. et al., “Bone Marrow in Polycythemia Vera, Chronic Myelocytic Leukemia, and Myelofibrosis Has an Increased Vascularity,”American Journal of Pathology, 2000, vol. 157(1), pp. 15-19.
Dankbar, B. et al., “Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell Interactions in multiple myeloma,”Blood, 2000, vol. 5(8), pp. 2630-2636.
Menzel, T. et al., “Elevated Intracellular Level of Basic Fibroblast Growth Factor Correlates with Stage of Chronic Lymphocytic Leukemia and is Associated With Resistance to Fludarabine,”Blood, 1996, vol. 87(3), pp. 1056-1063.
Gruber, G. et al., “Basic Fibroblast Growth Factor is Expressed in CD19/CD11c-Positive Cells in Hairy Cell Leukemia,”Blood, 1999, vol. 94(3), pp. 1077-1085.
Machajewski Timothy D.
McBride Christopher
McCrea, Jr. William R.
Pecchi Sabina
Poon Daniel J.
Chiron Corporation
Friedrichsen Bernard P.
Harbin Alisa A.
Suh Young J.
Ward Paul V.
LandOfFree
Indazole benzimidazole compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Indazole benzimidazole compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indazole benzimidazole compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3662092